Kaarina Partanen

Biochemistry, Genetics and Molecular Biology · Life Sciences

58h-index10.9kcitations214works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(58), Cancer Research and Treatments(50), CAR-T cell therapy research(30), Viral Infectious Diseases and Gene Expression in Insects(27), Epilepsy research and treatment(24)

Publications214 total

A Participatory Survey to Investigate the Long-Term Effectiveness of Adult Psychiatric Services (PSILEAPS): Baseline Data and Recruitment Experiences
Community Mental Health Journal·2025· 1 citedOpen Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Hilkka Soininen(18), Mikko P. Laakso(16), Pauli Vainio(15), Tuomo Hänninen(10), Asla Pitkänen(9), Akseli Hemminki(9), Merja Hallikainen(8), Timo Joensuu(8), Maarit Lehtovirta(7), Lotta Kangasniemi(7), Vincenzo Cerullo(7), Iulia Diaconu(7), Minna Oksanen(7), Leena Laasonen(7), Anna Kanerva(7), Reetta Kälviäinen(7), Paavo Riekkinen(6), P. Riekkinen(5), Anniina Koski(5), Sari Pesonen(5)